QualityStocks'  Instablog

NeoStem's dedication is to continually developing and building its core capabilities in cell therapy to capitalize on the paradigm shift occurring in medicine. Through wholly owned subsidiary Progenitor Cell Therapy (PCT), NeoStem leverages 12 years of exclusive cell therapy-focused experience to bridge the gap between the concepts in the cell therapy industry and their therapeutic application in patient care.

PCT provides a broad range of services in the cell therapy market for the treatment of human disease. Through the use of its network of contacts throughout the cell therapy industry, the company is able to identify early stage development opportunities in the cell therapy field and develop these cell therapies through proof-of-concept. From that point, products can be further developed and ultimately commercialized through NeoStem's developing commercial structure.

Amorcyte, LLC, which NBS acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, is NeoStem's most clinically advanced therapy and has initiated enrollment for a Phase II trial to investigate AMR-001′s efficacy in preserving heart function after a heart attack. It's anticipated that NBS will begin a Phase 1 clinical trial by 2013 to investigate AMR-001′s utility in arresting the progression of congestive heart failure and the associated co-morbidities of that disease.

Cell therapy promises to have large role in the fight against chronic disease and reducing the exorbitant expenses of our current healthcare system. NeoStem is ideally positioned to lead the cell therapy industry with its strong basic research capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise, and more than a decade of experience in clinical practice.

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net